Home › Funds › Frazier Life Sciences Management, L.P. › NAMS

Frazier Life Sciences Management, L.P. position in NAMS

NEWAMSTERDAM PHARMA COMPANY · Health Care

Frazier Life Sciences Management, L.P. reported holding 18,088,902 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q2 2026 13F filing — a position valued at US$613.0M, representing 13.35% of its reported portfolio and ranking #2 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed NAMS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)18.09M sh
Reported value held$613.03M
Portfolio Weight13.35%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Frazier Life Sciences Management, L.P.'s NAMS position evolved

Frazier Life Sciences Management, L.P. first disclosed a stake in NAMS in Q3 2023 at 12,131,705 shares (US$112.2M). The position peaked in Q2 2026 at 18,088,902 shares, worth US$613.0M. Across 12 filings, Frazier Life Sciences Management, L.P. increased the stake 8 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 18,088,902 shares valued at US$613.0M — an increase of 1,145,128 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 12.13M $112.22M New
Q4 2023 12.13M $135.51M Hold
Q1 2024 12.23M $289.17M Add
Q2 2024 12.23M $234.88M Hold
Q3 2024 12.86M $213.40M Add
Q4 2024 15.92M $409.05M Add
Q1 2025 16.12M $329.90M Add
Q2 2025 16.61M $300.75M Add
Q3 2025 16.70M $475.00M Add
Q4 2025 16.94M $594.39M Add
Q1 2026 16.94M $542.37M Hold
Q2 2026 18.09M $613.03M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NAMS and 13F data

NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 43 other funds we track also report a position in NAMS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$144.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NAMS

All NAMS fund holders →

FAQ

How long has Frazier Life Sciences Management, L.P. held NAMS?

Frazier Life Sciences Management, L.P. has disclosed NAMS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Frazier Life Sciences Management, L.P.'s current position in NAMS?

As of Q2 2026, Frazier Life Sciences Management, L.P. holds 18.09M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $613.03M, representing 13.35% of its reported portfolio and ranking #2.

Has Frazier Life Sciences Management, L.P. been buying or selling NAMS?

In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. increased its position in NAMS. The position peaked in Q2 2026 at 18.09M shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., DEERFIELD MANAGEMENT COMPANY, L.P., among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.